| Bioactivity | TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research[1]. |
| Invitro | TJ191(0-100 µM; 24 hours) exhibits pronounced anti-proliferative activity in malignant cell lines, the IC50 values are 0.13 µM, 0.13±0.08 µM, 0.26±0.19 µM, 0.22±0.11 µM, 1.5±0.02 µM, 0.32±0.086 µM, 3.1±0.5 µM, 0.26±0.16 µM in CEM, JURKAT, MOLT-3, MOLT-4, SUP-T1, MT-2, C8166 and HSB-2 cells, respectively. But has no effects in HUT-78 (IC50=17±10 µM) and MT-4 (IC50=47 ± 5 µM) cells[1].TJ191 (0.1-3 µM; 8 or 24 hours) induces CEM cell apoptosis in a concentration- and time-dependent manner. Even at 0.3 µM, TJ191 induces the maximum apoptotic rate of 80% after 24 h[1]. Cell Viability Assay[1] Cell Line: |
| Name | TJ191 |
| CAS | 1522415-97-9 |
| Formula | C13H21NO2S |
| Molar Mass | 255.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |